An Australian stem cell and regenerative medicine company
April 03, 2020
Cynata Therapeutics (ASX:CYP) 1H20 results & outlook
Finance News Network discusses with Cynata CEO Dr Ross Macdonald the Company’s 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform